The potential use of psychedelics for the treatment of various CNS indications is filling the drug development pipeline. Researchers in the field are examining modified chemical structures and analogs to psychedelics, to demonstrate efficacy and mitigate potential side effects.

In this podcast, Altasciences’ and DevelRx’s scientific experts examine the preclinical, clinical, and regulatory requirements and strategies that second-generation psychedelics may utilize to differentiate their pharmacological profile. We examine how to demonstrate efficacy and generate safety data that may distinguish psychedelics from first generation candidates. 

Listen now

Speak with an expert about your research needs.

You may also be interested in the following:

• Blog: Clinical Applications of Hallucinogens, Dissociatives, and other Schedule I Drugs
• Webinar: Navigating Early Phase CNS-Active Drug Development with Dr. Beatrice Setnik, CSO
• The Altascientist: CNS, Hallucinogens, and Other Schedule I Drugs
• Fact Sheet: Central Nervous System Capabilities

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

In an industry where there is no shortage of drug development and manufacturing partners, you may ask:
WHY ALTASCIENCES?

Here are a few reasons:

• We are highly skilled in handling complex formulations and highly potent compounds, and have tested or manufactured a wide variety of dosage forms.
• We offer significant expertise in the production of liquid-filled capsules, using cutting-edge technology for an exceptionally high “Right First Time” rate in releasing quality batches.
• We can resolve your solubility and bioavailability challenges with techniques such as nanomilling.
• We offer fully integrated, end-to-end solutions, from discovery to preclinical to clinical proof of concept, and beyond. You will benefit from working with one partner to get your drug product to clinic, faster.

Watch to learn more on our expertise and how we can accelerate your drug development program.

Interested in speaking with one of our experts? Contact Us.

Approximately 25 % of drugs in development worldwide are classified as highly potent active pharmaceutical ingredients (HPAPIs), and present substantial challenges and safety concerns to the pharmaceutical manufacturing industry.

At Altasciences, handling and developing HPAPIs into finished drug product, such as anti-cancer compounds and narcotics, is one of our core strengths. Our unique expertise, segregated grade C/D clean rooms, safety procedures, and advanced technology allow us to take your potent compounds from concept to commercial scale manufacturing, safely.

Learn more about our HPAPI handling and manufacturing capabilities here.

Need help with your HPAPI?

CHAT WITH AN EXPERT

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.